What is Deep Pharma Intelligence?
Deep Pharma Intelligence, a subsidiary of Deep Knowledge Group, operates as a specialized market intelligence agency focused on the dynamic pharmaceutical, biotech, and healthcare industries. The company excels in biotech innovation profiling, market intelligence, and development advisory services. Leveraging advanced data mining, visualization systems, and interactive analytics tools, Deep Pharma Intelligence delivers deep technical insights and strategic guidance. Its core mission is to support clients navigating high-growth areas within the biotech and healthcare sectors through sophisticated AI and big data analytics platforms and reports.
How much funding has Deep Pharma Intelligence raised?
Deep Pharma Intelligence has raised a total of $50M across 1 funding round:
Series D
$50M
Series D (2026): $50M with participation from HSG, CDH Investments, and XIN DING Capital
Key Investors in Deep Pharma Intelligence
HSG
HSG is a leading exterior building service company in Southern California, specializing in waterproofing, restoration, and window cleaning. With over 40 years of experience, they cater to building owners and property managers, providing a comprehensive range of services including pressure washing and bird control.
CDH Investments
Founded in 2002, CDH Investments is headquartered in Hong Kong, China. They are an investment firm working in many areas including private equity, real estate, public equity, wealth management, and more.
XIN DING Capital
嘉言妙道 is an AI professional service organization dedicated to providing market value management and comprehensive solutions for Chinese listed companies. They offer consulting and digital solutions to over 1,500 listed and pre-listed companies, focusing on strategic planning, digital intelligence, and globalization.
What's next for Deep Pharma Intelligence?
The substantial enterprise-level capital infusion, particularly the recent strategic investment, indicates that Deep Pharma Intelligence is poised for a significant scaling phase. This financing will likely be directed towards enhancing its AI-driven analytics capabilities, expanding its data acquisition efforts, and broadening its client advisory services. The company is expected to deepen its market penetration, potentially exploring new geographical markets or expanding its service offerings to encompass adjacent sectors within the life sciences. This strategic backing suggests a focus on solidifying its position as a leading provider of intelligence and strategic guidance in the complex and rapidly evolving biotech and healthcare landscape.
See full Deep Pharma Intelligence company page
